Elite Pharma Stock Working Capital
| ELTPDelisted Stock | USD 0.04 0 6.75% |
Elite Pharma fundamentals help investors to digest information that contributes to Elite Pharma's financial success or failures. It also enables traders to predict the movement of Elite OTC Stock. The fundamental analysis module provides a way to measure Elite Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Elite Pharma otc stock.
Elite |
Elite Pharma OTC Stock Working Capital Analysis
Elite Pharma's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Elite Pharma Working Capital | 14.53 M |
Most of Elite Pharma's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Elite Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionAccording to the company's disclosures, Elite Pharma has a Working Capital of 14.53 M. This is 96.59% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The working capital for all United States stocks is 99.02% higher than that of the company.
Elite Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Elite Pharma's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Elite Pharma could also be used in its relative valuation, which is a method of valuing Elite Pharma by comparing valuation metrics of similar companies.Elite Pharma is currently under evaluation in working capital category among its peers.
Elite Fundamentals
| Return On Equity | 0.27 | ||||
| Return On Asset | 0.0739 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 27.92 M | ||||
| Shares Outstanding | 1.01 B | ||||
| Shares Owned By Insiders | 17.53 % | ||||
| Shares Owned By Institutions | 0.06 % | ||||
| Number Of Shares Shorted | 757.07 K | ||||
| Price To Earning | 5.21 X | ||||
| Price To Book | 1.12 X | ||||
| Price To Sales | 0.92 X | ||||
| Revenue | 32.26 M | ||||
| Gross Profit | 14.8 M | ||||
| EBITDA | 7.93 M | ||||
| Net Income | 8.9 M | ||||
| Cash And Equivalents | 19.78 M | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 1.39 M | ||||
| Debt To Equity | 0.57 % | ||||
| Current Ratio | 4.50 X | ||||
| Book Value Per Share | 0.03 X | ||||
| Cash Flow From Operations | 6.51 M | ||||
| Short Ratio | 0.87 X | ||||
| Earnings Per Share | 0.01 X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 43 | ||||
| Beta | 0.29 | ||||
| Market Capitalization | 38.53 M | ||||
| Total Asset | 35.15 M | ||||
| Retained Earnings | (147.41 M) | ||||
| Working Capital | 14.53 M | ||||
| Current Asset | 19.66 M | ||||
| Current Liabilities | 5.13 M | ||||
| Z Score | 10.6 | ||||
| Net Asset | 35.15 M |
About Elite Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elite Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elite Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elite Pharma based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Elite Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Elite Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Elite Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Elite OTC Stock
| 0.68 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.67 | DYNT | Dynatronics | PairCorr |
| 0.63 | SXTC | China SXT Pharmaceuticals | PairCorr |
| 0.58 | BGXX | Bright Green Corp | PairCorr |
| 0.57 | RMTI | Rockwell Medical | PairCorr |
The ability to find closely correlated positions to Elite Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Elite Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Elite Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Elite Pharma to buy it.
The correlation of Elite Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Elite Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Elite Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Elite Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Elite OTC Stock
If you are still planning to invest in Elite Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Elite Pharma's history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |